Free Trial
NASDAQ:CLDX

Celldex Therapeutics Q4 2023 Earnings Report

Celldex Therapeutics logo
$20.29 -0.88 (-4.16%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$20.27 -0.02 (-0.07%)
As of 06/27/2025 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.76
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$4.13 million
Expected Revenue
$1.20 million
Beat/Miss
Beat by +$2.93 million
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, February 26, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Celldex Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Celldex Therapeutics Earnings Headlines

CLDX Celldex Therapeutics, Inc. - Seeking Alpha
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat